Key facts
- Axent Biosciences’s last known valuation is $38.0M.
- It has raised $17.2M; the latest was Seed Round ($6.0M) in Sep 2024.
- Notable investors include Berkeley SkyDeck, Berkeley Frontier Fund, venBio, Berkeley SkyDeck Fund, Kerna Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Axent Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Axent Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axent Biosciences
Developer of stem cell therapies designed to address unmet medical needs in human health. The company's platform uses technology in stem cell manufacturing and implantation to leverage years of stem cell and biomaterials engineering expertise to overcome major bottlenecks in the clinical development pipeline, enabling patients in need with stem cell therapeutics.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 10
- Website
- axentbiosciences.com/
- Ownership
- Privately Held (backing)
Axent Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axent Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axent Biosciences in its N-PORT filings yet. We sweep new filings monthly.